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The neuropeptides orexin A and orexin B (also known as hypocretin 1 and hypocretin 2), 
produced in lateral hypothalamic neurons, are critical regulators of feeding behavior, the 
reward system and sleep/wake states. Orexin-producing neurons (orexin neurons) are 
regulated by various factors involved in regulation of energy homeostasis and 
sleep/wakefulness states. Bombesin receptor subtype 3 (BRS3) is an orphan receptor that 
might be implicated in energy homeostasis, and is highly expressed in the hypothalamus. 
However, the neural pathway by which BRS3 regulates energy homeostasis is largely 
unknown. We examined whether BRS3 is involved in the regulation of orexin neurons. 
Using a calcium imaging method, we found that a selective BRS3 agonist 
(Ac-Phe-Trp-Ala-His-(Bzl)-Nip-Gly-Arg-NH2) increased the intracellular calcium 
concentration of orexin neurons. However, intracellular recordings from slice 
preparations revealed that the BRS3 agonist hyperpolarized orexin neurons. The BRS3 
agonist depolarized orexin neuron in the presence of tetrodotoxin. Moreover, in the 
presence of GABA receptor blockers, picrotoxin and CGP55845, the BRS3 agonist 



































































hybridization study revealed that Brs3 mRNA was expressed in almost all orexin neurons 
and many cells around these neurons. These findings suggest that the BRS3 agonist 
indirectly inhibited orexin neurons through GABAergic input and directly activated 
orexin neurons. Inhibition of activity of orexin neurons through BRS3 might be an 
important pathway for regulation of feeding and sleep/wake states. This pathway might 




































































The neuropeptides orexin A and orexin B were identified as endogenous ligands for two 
orphan G-protein-coupled receptors (GPCRs) (Sakurai, 1998). Orexin-producing 
neurons (orexin neurons) are localized exclusively in the lateral hypothalamic area 
(LHA), which is known as the feeding center. Various evidence has suggested that this 
neuropeptide is involved in the regulation of feeding behavior (Sakurai, 1998; Edwards, 
1999; Haynes, 2000; Haynes, 2002). Subsequently, the finding that orexin deficiency 
causes narcolepsy in humans and animals suggested that these hypothalamic 
neuropeptides also play a critical role in regulating sleep and wakefulness (Chemelli, 
1999; Lin, 1999; Peyron, 2000; Thannickal, 2000; Hara, 2001).  
Recent studies of the efferent and afferent systems of orexin-producing neurons, 
as well as phenotypic characterization of mice with genetic alterations in the orexin 
system, have suggested further roles of orexin in the coordination of emotion, energy 
homeostasis, reward, drug addiction, and arousal. Orexin neurons receive abundant input 
from the limbic system, preoptic sleep-promoting neurons, and hypothalamic neurons 



































































metabolic cues, including ghrelin, leptin and glucose, suggesting that orexin neurons 
might provide a link between energy homeostasis and sleep/wake states (Yamanaka, 
2003b).  
Bombesin receptor subtype 3 (BRS3) is a member of the bombesin receptor 
subfamily of GPCRs, which also includes the neuromedin B- and gastrin-releasing 
peptide receptors (NMBR and GRPR) (Gorbulev, 1992). BRS3 couples to endogenous 
Gq family proteins and increases intracellular calcium concentration. BRS3 has a unique 
pharmacological profile and does not bind with high affinity with any known 
bombesin-related peptides. Although a number of molecules that can activate human 
BRS3 have been developed (Mantey, 1997; Liu, 2002; Weber, 2003; Boyle, 2005; 
Gonzalez, 2008; Zhang, 2009), its natural ligands are still unknown (Jensen, 2008).  
BRS3 is primarily expressed in the CNS, and is present in the highest amounts 
in the hypothalamic area where orexin neurons are localized (Ohki-Hamazaki, 1997a; 
Yamada, 1999; Liu, 2002; Jennings, 2003; Sano, 2004). Although the normal 
physiological function of BRS3 is largely unknown, mice lacking the BRS3 gene develop 



































































(Ohki-Hamazaki, 1997b). In good agreement with the Brs3
-/-
 mouse study, a BRS3 
agonist, Bag-1, reduced food intake and increased metabolic rate (Guan, 2010). These 
studies suggested that BRS3 might be an important regulator of feeding behavior and 
energy homeostasis. A recent study showed that the anorectic effects of the BRS3 agonist 









 and leptin receptor
db/db
 mice (Guan, 2010). These results 
suggest that the effect of the BRS3 agonist might be mediated through other feeding 
mechanisms. However, the neural pathways of feeding behavior mediated by BRS3 are 
largely undefined. The orexin pathway is one of the possible pathways by which the 
BRS3 agonist evokes its effects, because orexin neurons are regulated by several factors 
involved in energy metabolism, and expression of BRS3 were found in the LHA. To 
investigate this possibility, we evaluated the effect of a BRS3 agonist on orexin neurons. 
In this study, we found that a BRS3 agonist activated orexin neurons directly, while it 
also inhibited these neurons through activation of local GABAergic internerons.  
 




































































The BRS3 agonist, neuromedin B (Peptide Institute, Osaka, Japan), tetrodotoxin (TTX) 
(Wako, Osaka, Japan), picrotoxin (Sigma, St. Louis, MO), and CGP55845 (Wako) were 
dissolved in extracellular solution. We also used a synthesized a selective BRS3 agonist 
(Ac-Phe-Trp-Ala-His (Bzl)-Nip-Gly-Arg-NH2) (Boyle, 2005). 
Animals 
All experimental procedures involving animals were approved by the Kanazawa 
University Animal Care and Use Committee and were in accordance with NIH guidelines. 
All efforts were made to minimize animal suffering and discomfort and to reduce the 
number of animals used. Genetically-modified mice used in this study were 
Orexin/YC2.1 mice (Tsujino, 2005) and Orexin/EGFP mice (Yamanaka, 2003a). 
In situ hybridization 
Double in situ hybridization was performed according to procedures previously described 
(Mieda, 2006). Digoxigenin (DIG)-labeled riboprobes for mBrs3 were synthesized from 
a 1196 bp fragment of murine Brs3 cDNA (nucleotides –172 - +1367 from the initiation 



































































(Invitrogen). Fluorescein (FITC)-labeled riboprobes for prepro-Orexin were synthesized 
by in vitro transcription. pBluescript II SK (+) containing a 0.5 kb fragment encoding 
Gln33-Val130 of prepro-Orexin was used as a template for in vitro transcription (Sakurai, 
1998). The DIG and FITC-labeled probes were detected by means of anti-DIG (1/2000) 
and anti-FITC (1/1000) antibodies conjugated with alkaline phosphatase (Roche 
Diagnostics, Basel, Switzerland). Alkaline phosphatase activity was detected with 
NBT/BCIP and INT/BCIP (Roche Diagnostics). 
Brain slice preparation 
Orexin/YC2.1 mice (3-8 weeks old) and Orexin/EGFP mice (3-6 weeks old) were 
anesthetized with forane (Abbott, Osaka, Japan). The mice were decapitated under deep 
anesthesia. Brains were isolated in ice-cold cutting solution consisting of (mM): 280 
sucrose, 2 KCl, 10 HEPES, 0.5 CaCl2, 10 MgCl2, 10 glucose, pH 7.4, bubbled with 100% 
O2. Brains were cut coronally into 300-µm slices with a vibratome (VTA-1000S, Leica, 
Germany). Slices containing the LHA were transferred for 1 hr to an incubation chamber 
at room temperature filled with physiological solution containing (mM): 125 NaCl, 2.5 



































































with 95% O2/5% CO2. 
Calcium imaging of orexin neurons 
Optical recordings were performed on a fluorescence microscope (BX51WI, Olympus, 
Tokyo, Japan) equipped with a cooled charge-coupled device (CCD) camera (CoolSNAP 
HQ2, Roper Scientific, Tucson, AZ) controlled by MetaFluor 5.0.7 software (Universal 
Imaging, West Chester, PA). YC2.1 was excited through a 440DF20 filter, and its 
fluorescent image was subjected to dual emission ratio imaging through two emission 
filters (480DF30 for ECFP, 535DF26 for EYFP) controlled by a filter changer (ProscanII, 
Prior Scientific Instruments, Cambridge, UK). 
Electrophysiological recording 
Orexin/EGFP mice were used for whole cell recordings. The slices were transferred to a 
recording chamber (RC-27L, Warner Instrument Corp., CT, USA) at room temperature 
on a fluorescence microscope stage (BX51WI, Olympus, Tokyo, Japan). Neurons that 
showed GFP fluorescence were used for patch-clamp recordings. The fluorescence 
microscope was equipped with an infrared camera (C-3077, Hamamatsu Photonics, 



































































CCD camera (JK-TU53H, Olympus) for fluorescent imaging. Each image was displayed 
separately on a monitor. Recordings were carried out with an Axopatch 700B amplifier 
(Axon Instruments, Foster City, CA) using a borosilicate pipette (GC150-10, Harvard 
Apparatus, Holliston, MA) prepared by a micropipette puller (P-97, Sutter Instruments, 
Pangbourne, UK) and filled with intracellular solution (4-10 MΩ), consisting of (mM): 
125 K-gluconate, 5 KCl, 1 MgCl2, 10 HEPES, 1.1 EGTA-Na3, 5 MgATP, 0.5 Na2GTP, 
pH7.3 with KOH. Osmolarity of the solution was checked by a vapor pressure osmometer 
(model 5520, Wescor, Logan, UT). The osmolarity of the internal and external solutions 
was 280-290 and 320-330 mOsm/l, respectively. The liquid junction potential of the 
patch pipette and perfused extracellular solution was estimated to be -16.2 mV and was 
applied to the data. The recording pipette was under positive pressure while it was 
advanced toward an individual cell in the slice. A tight seal of 0.5-1.0 GΩ was made by 
applying negative pressure. The membrane patch was then ruptured by suction. The 
series resistance during recording was 10-25 MΩ and was compensated. The reference 
electrode was an Ag-AgCl pellet immersed in the bath solution. During recordings, cells 
were superfused with extracellular solution at a rate of 1.0-2.0 ml/min
 



































































pump (K.T. Lab, Japan) at RT.  
 
RESULTS 
Selective BRS3 agonist influences activity of orexin neurons by direct and indirect 
pathways 
Recent studies have suggested that the activity of orexin neurons is influenced by various 
factors involved in sleep/wake states or feeding behavior. It is also possible that BRS3 
may regulate the activity of orexin neurons, because Brs3
-/-
 mice developed obesity and 
impairment of glucose metabolism (Ohki-Hamazaki, 1997b). To examine the possibility 
that BRS3 is involved in regulation of the activity of orexin neurons, we applied a 
selective BRS3 agonist (Ac-Phe-Trp-Ala-His (Bzl)-Nip-Gly-Arg-NH2) to orexin 
neurons using brain slice preparations of Orexin/YC2.1 transgenic mice, in which orexin 
neurons specifically express the calcium-indicator protein, yellow cameleon (YC) 2.1 
(Tsujino, 2005), and observed the change in intracellular calcium concentration ([Ca
2+
]i) 
of orexin neurons. In the presence of tetrodotoxin (TTX), the BRS3 agonist increased the 
YFP/CFP ratio, showing that [Ca
2+





































































]i was concentration-dependent (Fig. 1B) (n=3-6). Of YFP-positive 
neurons tested, 91.8% were activated by the BRS3 agonist (n=49), but they showed no 
response to neuromedin B, an NMBR agonist (n=11).  
We also studied the effect of the BRS3 agonist on orexin neurons in detail by 
slice patch clamp recording. Unexpectedly, BRS3 agonist (1M) bath application 
potently hyperpolarized and decreased the firing frequency of orexin neurons under the 
whole cell current clamp mode (n=7, Fig. 2A). On the other hand, the BRS3 agonist 
(1M) induced depolarization of orexin neurons in the presence of TTX (Fig. 2B). 
Furthermore, the BRS3 agonist (1M) induced depolarization and increased the firing 
frequency of orexin neurons in the presence of both picrotoxin and CGP55845 (GABAA 
and GABAB receptor blockers, respectively) (Fig. 2C). These observations suggest that 
the BRS3 agonist induced depolarization of orexin neurons directly, but more potently 
hyperpolarized these neurons through activation of GABAergic interneurons. 
Brs3 and Orexin are colocalized in lateral hypothalamic neurons 
To examine the tissue localization of BRS3, we performed double-label in situ 



































































CNS. Relatively large numbers of cells were found in the cortex, hippocampus, amygdala 
and LHA (Fig. 3A and B). We found that almost all neurons expressing Orexin mRNA 
expressed Brs3 mRNA (Fig. 3C and D). 
Discussion 
Although BRS3 still remains an orphan receptor, it is thought to be a possible drug target 
for treating obesity and the metabolic syndrome, because BRS3-deficient mice show late 
onset obesity and impaired glucose metabolism. 
In the present study, we found that a selective BRS3 agonist hyperpolarized all 
orexin neurons under current clamp recording (Fig. 2A) but depolarized them in the 
presence of GABA receptor antagonists, picrotoxin and CGP55845 (Fig. 2C). This result 
suggests that the inhibitory effect on orexin neurons was mediated by activation of 
GABAergic input. Consistently, under inhibition of neural input by TTX, the effect of the 
agonist on orexin neurons was excitatory, and intracellular Ca
2+
 of orexin neurons was 
increased presumably through activation of the Gq-subfamily of G- proteins (Fig. 2B). In 
situ hybridization study revealed that Brs3 mRNA was expressed widely in hypothalamic 



































































Yamada, 1999; Guan, 2010; Jennings, 2003; Sano, 2004). Double-label in situ 
hybridization study showed that almost all orexin neurons also expressed Brs3 mRNA 
(Fig. 3C and D). Both electrophysiological and histochemical analyses suggested that the 
BRS3 agonist activated orexin neurons directly through activation of BRS3 on orexin 
neurons. However, the direct depolarizing effect of the BRS3 agonist appeared only when 
neural input was suppressed by TTX or a GABA blocker. This suggests that the indirect 
inhibitory effect predominated over the direct excitatory effect. Consistently, we 
observed many BRS3-positive neurons in the LHA by in situ hybridization, which could 
possibly be GABAergic interneurons, although further studies are required to reveal the 
origin of GABAergic input to orexin neurons. 
From a physiological viewpoint, unknown natural ligands of BRS3 also might 
inhibit the activity of orexin neurons and suppress feeding behavior. Although a recent 
report suggested that a BRS3 agonist increased inhibitory synaptic transmission of the 
arcuate nucleus (Guan, 2010), other pathways regulating feeding behavior have not yet 
been clarified. This study revealed a new pathway of a BRS3 agonist. Our results also 









































































































































FRET calcium imaging study showing that the BRS3 agonist influenced orexin neuron 
activity, using a hypothalamic slice from Orexin/YC2.1 mice. A, In the presence of 
tetrodotoxin (TTX), bath application of the BRS3 agonist (1M) increased the YFP/CFP 
ratio, suggesting that the BRS3 agonist (1M) increased [Ca2+]i in orexin neurons. B, The 




A, Under whole cell current clamp mode, the BRS3 agonist (1M) induced 
hyperpolarization of orexin neurons and decreased firing frequency. B, In the presence of 
TTX, orexin neurons were depolarized by the BRS3 agonist (1M). C, In the presence of 
both picrotoxin (GABAA blocker) and CGP55845 (GABAB blocker), the BRS3 agonist 





































































Double-label in situ hybridization histochemistry showing distributions of Orexin 
(brown) and Brs3 (blue) mRNA. A, Brs3 mRNA was distributed widely in the CNS, 
especially in the cortex, hippocampus, amygdala and LHA. B, Schematic representation 
of distribution of Brs3 and Orexin mRNA (bregma -1.34 mm). C. High power view of 
lateral hypothalamic area. D, High power view of region in rectangle in C. Orexin mRNA 
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